安进2024年第三季度调整后每股收益5.58美元，超过5.11美元的预估，销售额85亿美元
但低于85.2亿美元的预估
Amgen Q3 2024 Adj EPS $5.58 Beats $5.11 Estimate, Sales $8.50B Miss $8.52B Estimate
Amgen Q3 2024 Adj EPS $5.58 Beats $5.11 Estimate, Sales $8.50B
Miss $8.52B Estimate
"Strong growth in sales and earnings this quarter reflects the momentum we're building throughout our business. We continue to invest heavily in our rapidly advancing pipeline, with a focus on delivering innovative therapies across our core therapeutic areas," said Robert A. Bradway, chairman and chief executive officer.$Amgen (AMGN.US)$ reported Q3 earnings after the bell, with earnings per share and sales rising.
$安进 (AMGN.US)$ 在报告了第3季度收益之后，每股收益和销售额均上升。
Q3 earnings of $5.58 per share beat the analyst consensus estimate of $5.11 by 9.2 percent.
每股收益为5.58美元，超出分析师共识估计的5.11美元，涨幅为9.2%。
The company reported Q3 sales of $8.50 billion, missing the analyst consensus estimate of $8.52 billion by 0.19 percent. This represents a 23.18 percent increase over sales of $6.90 billion in the same period last year.
该公司报告第3季度销售额为85亿美元，低于分析师的85.2亿美元共识估计，下降幅度为0.19%。这相当于去年同期销售额69亿美元的增长23.18%。
"Strong growth in sales and earnings this quarter reflects the momentum we're building throughout our business. We continue to invest heavily in our rapidly advancing pipeline, with a focus on delivering innovative therapies across our core therapeutic areas," said Robert A. Bradway, chairman and chief executive officer.
“本季度销售和收益的强劲增长反映了我们在业务各个领域不断积累的动力。我们继续大力投资于不断发展的产品线，致力于为我们的核心治疗领域提供创新疗法，” 安进主席兼首席执行官Robert A. Bradway表示。
Looking ahead for the full year 2024, Amgen now expects:
展望2024年全年，安进现在预计：
Total revenues in the range of $33.0 billion to $33.8 billion.
On a GAAP basis, EPS in the range of $8.71 to $9.56
营业收入在330亿到338亿美元的区间内。
按照通用会计准则，每股收益范围在8.71美元至9.56美元之间
In after-hours trading at 4:20 p.m. ET, shares are trading at $314, off 0.49%.
在下午4:20的盘后交易中，安进股票的价格为314美元，下跌0.49%。
资讯热榜
更新时间